Quick Comparison
| Piracetam | PQQ | |
|---|---|---|
| Half-Life | 4-5 hours | 3-5 hours (plasma), but effects on mitochondrial biogenesis persist |
| Typical Dosage | Standard: 1200-4800 mg daily in 2-3 divided doses. Clinical studies commonly use 2400-4800 mg daily. The 'attack dose' protocol uses 4800 mg daily for the first week, then reduces to maintenance. | Standard: 10-20 mg daily. Often combined with CoQ10 (100-300 mg) for synergistic mitochondrial support. Higher doses (40 mg) are used in some research settings. |
| Administration | Oral (powder, capsules, tablets). Highly bioavailable orally with nearly 100% absorption. | Oral (capsules, softgels). Best absorbed on an empty stomach. BioPQQ is the most studied branded form. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Piracetam
Piracetam modulates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-D-aspartate) glutamate receptors through positive allosteric modulation, enhancing excitatory neurotransmission without direct agonism. It increases membrane fluidity of neuronal phospholipid bilayers by reducing membrane microviscosity, which improves ion channel function and signal transmission. Piracetam enhances acetylcholine receptor density and turnover in the hippocampus, upregulating both muscarinic (M1) and nicotinic receptor expression. It potentiates the cholinergic system through increased high-affinity choline uptake. Additionally, piracetam improves cerebral blood flow via nitric oxide-dependent vasodilation and enhances oxygen utilization (glucose metabolism) in aged or hypoxic brain tissue, supporting mitochondrial function.
PQQ
PQQ activates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master transcriptional regulator of mitochondrial biogenesis. PGC-1alpha coactivates NRF-1 and NRF-2, which drive expression of mitochondrial transcription factor A (TFAM) and nuclear-encoded mitochondrial genes—the process of creating new mitochondria in existing cells. This is unique among commercially available supplements. PQQ also provides antioxidant protection through extremely efficient redox cycling at the N5 position; it can undergo thousands of oxidation-reduction cycles before being exhausted, estimated at 5,000x the efficiency of vitamin C. PQQ activates the CREB (cAMP response element-binding protein) signaling pathway and may enhance NGF signaling, supporting BDNF expression, synaptic plasticity, and neuronal survival.
Risks & Safety
Piracetam
Common
Headache (often from insufficient choline intake), insomnia if taken late in the day, gastrointestinal discomfort.
Serious
Very rare — piracetam has an extremely favorable safety profile. May increase the effects of blood thinners.
Rare
Nervousness, agitation, weight gain.
PQQ
Common
Very few — PQQ has an excellent safety profile at standard doses. Mild headache, fatigue initially.
Serious
No serious adverse effects documented.
Rare
Insomnia, irritability.
Full Profiles
Piracetam →
The original nootropic, synthesized in 1964 by Corneliu Giurgea who coined the term 'nootropic.' Piracetam modulates glutamate and acetylcholine neurotransmission to enhance memory, learning, and cognitive fluidity. Widely prescribed in Europe for cognitive decline and used globally as a cognitive enhancer. One of the most studied nootropics with decades of clinical data.
PQQ →
Pyrroloquinoline quinone is a redox cofactor that is the only known compound that can stimulate the growth of new mitochondria (mitochondrial biogenesis) in existing cells. Since mitochondrial density and function decline with age, PQQ addresses a root cause of age-related cognitive decline. It also provides potent antioxidant protection — estimated to be 5,000x more efficient at redox cycling than vitamin C.